Comment
doi: 10.1056/NEJMp030043.
HIV infection--a new drug and new costs
- PMID: 12773643
- DOI: 10.1056/NEJMp030043
Item in Clipboard
Comment
HIV infection--a new drug and new costs
N Engl J Med.
.
No abstract available
Comment on
-
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.N Engl J Med. 2003 May 29;348(22):2175-85. doi: 10.1056/NEJMoa035026. Epub 2003 Mar 13. N Engl J Med. 2003. PMID: 12637625 Clinical Trial.
-
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.N Engl J Med. 2003 May 29;348(22):2186-95. doi: 10.1056/NEJMoa035211. N Engl J Med. 2003. PMID: 12773645 Clinical Trial.
-
Novel therapies based on mechanisms of HIV-1 cell entry.N Engl J Med. 2003 May 29;348(22):2228-38. doi: 10.1056/NEJMra022812. N Engl J Med. 2003. PMID: 12773651 Review. No abstract available.
Similar articles
-
Fusion inhibition--a major but costly step forward in the treatment of HIV-1.N Engl J Med. 2003 May 29;348(22):2249-50. doi: 10.1056/NEJMe030042. N Engl J Med. 2003. PMID: 12773653 No abstract available.
-
Fuzeon treatment forum, January 2004.Surviv News (Atlanta Ga). 2004 Jan-Feb;15(1):10. Surviv News (Atlanta Ga). 2004. PMID: 15032144 No abstract available.
-
Clinical trials for enfuvirtide (Fuzeon, T-20).AIDS. 2003 Nov 21;17(17):N13-4. AIDS. 2003. PMID: 15065580 No abstract available.
-
[Enfuvirtide, mechanism of action and pharmacological properties].Med Arh. 2005;59(5):313-6. Med Arh. 2005. PMID: 16134757 Review. Bosnian.
-
Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.Clin Infect Dis. 2003 Oct 15;37(8):1102-6. doi: 10.1086/378302. Epub 2003 Sep 10. Clin Infect Dis. 2003. PMID: 14523775 Review.
Cited by
-
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.Clin Drug Investig. 2007;27(7):469-79. doi: 10.2165/00044011-200727070-00004. Clin Drug Investig. 2007. PMID: 17563127 Clinical Trial.
-
Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.AIDS Res Treat. 2012;2012:595762. doi: 10.1155/2012/595762. Epub 2012 Nov 8. AIDS Res Treat. 2012. PMID: 23193464 Free PMC article.
-
IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies.PLoS Pathog. 2019 Dec 5;15(12):e1008082. doi: 10.1371/journal.ppat.1008082. eCollection 2019 Dec. PLoS Pathog. 2019. PMID: 31805154 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
